Trial results found that GM-CSF augmented ADCC activity of mononuclear cells and granulocytes against both colorectal cancer cells and neuroblastoma; therapeutic efficacy was demonstrated in these trials (Mellstedt et al, 1991; Ragnhammar et al, 1992; Yu et al, 1997). Here, CSF2 is linked to colorectal cancer.